In A First, Merck And AstraZeneca Team Up For Oncology Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The two Big Pharmas have allied for early development of Merck’s AKT inhibitor and AZ’s Mek inhibitor. But where do they go from there?